CJC-1295 / Ipamorelin — 8mg / 8mg

CJC-1295 / Ipamorelin is a co-formulated research compound containing two mechanistically complementary growth hormone secretagogues at equal concentrations. CJC-1295 is a modified 30-amino acid analog of growth hormone-releasing hormone (GHRH 1-29) that carries a tetrasubstitution pattern (D-Ala²-Gln⁸-Ala¹⁵-Leu²⁷) stabilizing it against dipeptidyl peptidase IV cleavage. Without the DAC (drug affinity complex) albumin-binding modification, this variant — often called CJC-1295 No-DAC or Modified GRF 1-29 — has a short half-life of approximately 30 minutes, which is deliberate: it produces a physiological GHRH-like pulse rather than tonic receptor stimulation.

Ipamorelin is a selective pentapeptide ghrelin receptor (GHSR-1a) agonist developed by Novo Nordisk. Unlike earlier growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin), Ipamorelin is notably selective — it produces robust GH release without elevating cortisol, prolactin, or aldosterone, which has made it the preferred ghrelin mimetic for research protocols where clean GH isolation is required. The two compounds work synergistically: CJC-1295 acts on GHRH receptors to drive somatotrope release of GH, while Ipamorelin simultaneously inhibits somatostatin and amplifies the GH pulse through the parallel ghrelin pathway.

The result of this dual mechanism is pulsatile GH release that closely mimics endogenous patterns — a mechanistically important feature, since tonic GH exposure produces different downstream effects than pulsatile exposure at the same AUC. Research applications span body composition, sleep architecture (GH is preferentially released during slow-wave sleep), post-injury recovery, and age-related decline in GH output. The 8mg/8mg co-formulation simplifies reconstitution and dosing: the equal-concentration pairing is the most widely used ratio in community protocols, typically dosed at 100–200 mcg of each peptide before sleep.